Ketamine for the Treatment of Depression in Parkinson's Disease
Mental Health & Behavioral Research | Alzheimer's Disease
What is the purpose of this trial?
The main purpose of this study is to examine the efficacy, safety and mechanistic underpinnings of a repeated dosing ketamine infusion paradigm compared to placebo in individuals with PD.
A subset of participants in each arm will undergo baseline and post-treatment PET and fMRI scans, to examine whether changes in synaptic density and reorganization of functional networks underlie ketamine's putative antidepressant effects in PD.
- Ages40 years - 70 years
- Trial withMichael J. Fox Foundation
- Start Date11/23/2021
- End Date08/31/2024
- Last Updated12/17/2021
- Study HIC#2000030394